Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Caplin Point Laboratories Ltd.

Granules India Ltd.

Medplus Health Services Ltd.

Procter & Gamble Health Ltd.

Glenmark Life Sciences Ltd.

Marksans Pharma Ltd.

Jubilant Pharmova Ltd.

Astrazeneca Pharma India Ltd.

Neuland Laboratories Ltd.

FDC Ltd.

Eris Lifesciences Ltd.

Wockhardt Ltd.

Natco Pharma Ltd.

Strides Pharma Science Ltd.

Aarti Drugs Ltd.

Market Cap	9,485 Cr	ROE	23.7%
P/E Ratio(TTM)	22.7	EPS(TTM)	0.0
P/B Ratio	4.6	Dividend Yield	0.4%
Industry P/E	40.6	Book Value	273.1
		Face Value	2.0

Fundamentals